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1298–309.The Addition of Niacin to Statin
Therapy Improves High-Density
Lipoprotein Cholesterol Levels
But Not Metrics of Functionality
To the Editor: The role of niacin in the era of widespread statin use
has been called into question by 2 recent clinical trials, AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome
With Low HDL/High Triglycerides: Impact on Global Health)
and HPS2-THRIVE (Treatment of HDL to Reduce the Inci-
dence of Vascular Events), indicating no added beneﬁt when niacin
was added to standard low-density lipoprotein (LDL) reduction
therapy with simvastatin and ezetimibe (1).
Mass-based assessment of high-density lipoprotein cholesterol
(HDL-C) levels may not fully capture substantial variability in
HDL functional properties. Cholesterol efﬂux capacity, a marker of
the ability of HDL to accept cholesterol from macrophages and
thus facilitate reverse cholesterol transport, served as a stronger
predictor of atherosclerotic burden than HDL-C levels in 2 inde-
pendent cohorts (2). This inverse association with coronary disease
prevalence was conﬁrmed using a related assay in 2 additional
cohorts by Li et al. (3); an unexpected direct association with
prospective events awaits further conﬁrmation. Furthermore, the
HDL inﬂammatory index, a surrogate for HDL’s antioxidant
capacity, was impaired in patients in the midst of an acute coronary
syndrome (4).
We conducted a study designed to assess the impact of niacin
added to statin therapy onHDL-C levels, cholesterol efﬂux capacity,
and the HDL inﬂammatory index. Samples were derived from
a previously described randomized controlled trial (NCT00307307)
(5). In brief, patients with carotid atherosclerosis were randomized
to simvastatin 20 mg daily plus either placebo or extended-release
(ER) niacin, titrated up to 2 g daily. HDL-C levels and func-
tional parameters were assessed at baseline and after 6 months of
therapy.
Cholesterol efﬂux capacity was quantiﬁed using a previously
validated cell-based assay that quantiﬁes the ability of apolipopro-
tein B–depleted plasma to accept radiolabeled cholesterol from
J774 macrophages ex vivo (3). Similarly, the HDL inﬂammatory
index measured the capacity of apolipoprotein B–depleted plasma
to inhibit the oxidation of puriﬁed LDL-C (4). All assays were
performed in duplicate. To control for interassay variation, sample
values were normalized to a pooled plasma control run on each
plate.
The association between HDL functional parameters and
baseline biomarkers was assessed using Pearson correlation coefﬁ-
cients. Paired Student t tests were used to analyze the effect
of pharmacotherapy on HDL parameters. These changes were
compared with placebo using an analysis of covariance test using
the patient’s baseline value and treatment group as covariates.
Baseline and 6-month plasma samples were available in 39
patients, 19 in the simvastatin plus ER niacin group and 20 who
received simvastatin plus placebo. Fifteen of the 19 patients (79%)
randomized to receive ER niacin achieved the target dose of 2 g
daily, with a mean achieved daily dose of 1.8 g. Baseline charac-
teristics were similar to those of the study population as a whole and
revealed no signiﬁcant difference between treatment groups.
The mean age of study participants was 71 years; 64% were male,
26% had diabetes, 69% had hypertension, 23% had a history of
coronary artery disease, and 67% were taking a statin at baseline.
Average total cholesterol was 185 mg/dl, with mean HDL-C
and LDL-C of 46 mg/dl and 116 mg/dl, respectively. Median
values for triglycerides and C-reactive protein were 135 mg/dl and
1.4 mg/l, respectively.
Substantial variation was noted across study participants in HDL
functional parameters. Mean normalized cholesterol efﬂux capacity
was 0.95, with a range of 0.57 to 1.54; average HDL inﬂammatory
index value was 1.15, with range of 0.70 to 2.81. The mean
Figure 1 Effect of Niacin on HDL-C Levels and Metrics of Functionality
Mean percent change from baseline for each treatment group is depicted for high-
density lipoprotein cholesterol (HDL-C) levels, cholesterol efﬂux capacity, and HDL
inﬂammatory index. *Indicates p value of < 0.05 for change compared with
placebo. CI ¼ conﬁdence interval; ER ¼ extended release.
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4.3% for HDL inﬂammatory index.
Bivariate correlation analysis demonstrated a moderate associa-
tion (r ¼ 0.56; p ¼ 0.002) between HDL-C levels and cholesterol
efﬂux capacity. However, no signiﬁcant association was noted
between HDL inﬂammatory index and either HDL-C levels
(r ¼ 0.18) or cholesterol efﬂux capacity (r ¼ 0.16). Only the
HDL inﬂammatory index was associated with log-transformed
values of C-reactive protein (r ¼ 0.37; p ¼ 0.02).
The impact of the 2 treatment regimens on HDL-C levels and
functional metrics are displayed in Figure 1. As expected, the
addition of niacin therapy led to a robust increase in average HDL-
C from 46 to 57 mg/dl (p ¼ 0.001 compared with baseline;
p ¼ 0.001 compared with placebo). However, no change was noted
in either cholesterol efﬂux capacity (mean change 1%; 95%
conﬁdence interval: 11% to 10%) or HDL inﬂammatory index
(mean change 9%; 95% conﬁdence interval: 6% to 24%).
These results thus indicate the feasibility of using 2 comple-
mentary assays of HDL function in a small drug study. The
addition of niacin to statin therapy led to favorable changes in
patients’ lipid proﬁles without a demonstrable effect on HDL
functionality, thus providing one potential mechanistic hypothesis
for the disappointing results in recent clinical trials.
The strengths of this study include its randomized, placebo-
controlled, prospective design and the use of robust assays with
previous relationship to cardiovascular disease phenotypes. Limita-
tions include small size, although the matched-pairs statistical plan
afforded 80% power to detect a 13% and 15% improvement
in cholesterol efﬂux capacity and HDL inﬂammatory index,
respectively. Furthermore, any potentially beneﬁcial effect of niacin
via LDL-C or lipoprotein(a) reduction would not have been detected
owing to the HDL speciﬁcity of the assays. (Carotid Atherosclerosis
Regression at Magnetic Resonance Assessment; NCT00307307).*Amit V. Khera, MDy
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687.e1–8.Letters to the Editor
Pregnancy in Arrhythmogenic
Right Ventricular Dysplasia/
CardiomyopathyWe read with interest the paper by Marcus et al. (1) published
in the May 14, 2013 issue of the Journal. The authors brought
to light the complex nature of clinical genetics in arrhythmogenic
right ventricular cardiomyopathy (ARVC) patients. Overall, this
paper provides an important review of the current state of clinical
genetic testing for this rare condition. We applaud the authors
for their conﬁrmation of the Heart Rhythm Society/European
Heart Rhythm Association guidelines (2) in recommending
genetic counseling when ordering genetic testing in this and other
cardiomyopathies.
